

*1.1m*

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/580,507	FIRST NAMED APPLICANT Amadeo Parissenti	ATTY. DOCKET NO. 12332006
---	--	------------------------------

INTERNATIONAL APPLICATION NO.

PCT/CA04/02039

I.A. FILING DATE

11/26/2004

PRIORITY DATE

11/26/2003

CONFIRMATION NO. 2338

371 FORMALITIES LETTER



\*OC000000022636177\*

MR. ADRIAN ZAHL  
RIDOUT & MAYBEE LLP  
150 METCALFE STREET  
19TH FLOOR  
OTTAWA ONTARIO, K2P 1P1  
CANADA

Date Mailed: 02/27/2007

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

APR 27 107  
W.D.



For Rules Interpretation, call (571) 272-0951

- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/580,507	PCT/CA04/02039	12332006

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:

Date: April 23, 2007

Name: Carolyn Reason-Wright

Signature:

*Carolyn Reason-Wright*

**BRINKS  
HOFFER  
GILSON  
& LIONE**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Appln. of: Amadeo Parissenti

Appln. No.: 10/580,507

Filed: November 26, 2004

For: **USE OF ISOGENIC DRUG-RESISTANT  
CELL LINES TO DETERMINE THE  
SEQUENCE OF CHEMOTHERAPEUTIC  
DRUG TREATMENT**

Examiner: Unknown

Art Unit: 1614

Attorney Docket No: 12332/006

Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL**

Sir:

**Attached is/are:**

- ☒ Response to Notification to Comply with Requirements for Patent Applications; Sequence Listing and Statement; 2 disks
- ☒ Return Receipt Postcard

**Fee calculation:**

- ☒ No additional fee is required.
- ☐ Small Entity.
- ☐ An extension fee in an amount of \$\_\_\_\_\_ for a \_\_\_\_\_-month extension of time under 37 C.F.R. § 1.136(a).
- ☐ A petition or surcharge in an amount of \$\_\_\_\_\_ under 37 C.F.R. § 1.16(e).
- ☐ An additional filing fee has been calculated as shown below:

					Small Entity		Not a Small Entity		
	Claims Remaining After Amendment	Minus	Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'l Fee
Total		Minus			x \$25=			x \$50=	
Indep.		Minus			x 100=			x \$200=	
First Presentation of Multiple Dep. Claim					+\$180=			+\$360=	
					Total	\$		Total	\$

**Fee payment:**

- ☐ A check in the amount of \$\_\_\_\_\_ to cover the above-identified fee(s) is enclosed.
- ☐ Please charge Deposit Account No. 23-1925 in the amount of \$\_\_\_\_\_. A copy of this Transmittal is enclosed for this purpose.
- ☐ Payment by credit card in the amount of \$\_\_\_\_\_ (Form PTO-2038 is attached).
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

*Nicholas M. Boivin*  
Nicholas M. Boivin (Reg. No. 45,650)

Date

4/23/2007

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313  
on April 23, 2007

  
  
Carolyn Beason-Wright

Case No. 12332/006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Amadeo Parissenti

Serial No.: 10/580,507

Attention: Manager,  
Application Branch

Filed: November 26, 2004

For: USE OF ISOGENIC DRUG-  
RESISTANT CELL LINES TO  
DETERMINE THE SEQUENCE OF  
CHEMOTHERAPEUTIC DRUG  
TREATMENT

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

MAIL STOP MISSING PARTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


In accordance with the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated February 27, 2007, a copy of which is attached, enclosed herewith for filing are the following documents:

- ☐ Fully executed Declaration for Patent Application for the above-referenced patent application.
- ☐ Fully executed Power of Attorney for the above-referenced patent application.
- ☒ Applicant:
  - ☒ claims small entity status. See 37 CFR1.27.

- ☐ is other than small entity
- ☐ Fees totaling \$\_\_\_\_\_ for:
- ☐ Filing Fee of \$\_\_\_\_\_.
- ☐ Surcharge of \$\_\_\_\_\_.
- ☐ Additional Claim Fees of \$\_\_\_\_\_.
- ☐ Search Fee of \$\_\_\_\_\_.
- ☐ Examination Fee of \$\_\_\_\_\_.
- ☐ Extension of Time Fee of \$\_\_\_\_\_.
- ☐ Application Size Fee (for each additional 50 sheets that exceeds 100 sheets, including specification and drawings) of \$\_\_\_\_\_.
- ☐ Petition for Extension of Time (37 C.F.R. § 1.136(a)) to file missing parts (in duplicate).
- ☒ Other: Sequence Listing and Statement, including 2 disks.
- ☒ The Commissioner is hereby authorized to charge the above fees or credit overpayment to Deposit Account No. 23-1925 in accordance with the attached Transmittal Sheet.

Respectfully submitted,

Dated: 4/23/2007

  
Nicholas M. Boivin  
Registration No. 45-650  
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE  
CUSTOMER NO. 27879  
317-636-0886